Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.
Acute treatment
China
Clinical trial
Migraine
Rimegepant
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
12
12
2023
accepted:
11
02
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
16
4
2024
Statut:
epublish
Résumé
Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries. Previously, a large clinical trial assessed the efficacy and safety of rimegepant ODT 75 mg for the acute treatment of migraine in adults living in China or South Korea. A post hoc subgroup analysis of this trial was performed to evaluate the efficacy and safety of rimegepant for acute treatment of migraine in adults living in China. Eligible participants were ≥ 18 years of age and had a ≥ 1-year history of migraine, with 2 to 8 attacks of moderate or severe pain intensity per month and < 15 headache days per month during the 3 months before screening. Participants self-administered rimegepant ODT 75 mg or matching placebo to treat a single migraine attack of moderate or severe pain intensity. The co-primary endpoints were pain freedom and freedom from the most bothersome symptom (MBS) at 2 h post-dose. Key secondary endpoints included pain relief at 2 h post-dose, ability to function normally at 2 h post-dose, use of rescue medication within 24 h post-dose, and sustained pain freedom from 2 to 24 h and 2 to 48 h post-dose. All p values were nominal. Safety was assessed via treatment-emergent adverse events (TEAEs), electrocardiograms, vital signs, and routine laboratory tests. Overall, 1075 participants (rimegepant, n = 538; placebo, n = 537) were included in the subgroup analysis. Rimegepant was more effective than placebo for the co-primary endpoints of pain freedom (18.2% vs. 10.6%, p = 0.0004) and freedom from the MBS (48.0% vs. 31.8%, p < 0.0001), as well as all key secondary endpoints. The incidence of TEAEs was comparable between the rimegepant (15.2%) and placebo (16.4%) groups. No signal of drug-induced liver injury was observed, and no study drug-related serious TEAEs were reported in the rimegepant group. A single dose of rimegepant 75 mg rimegepant was effective for the acute treatment of migraine in adults living in China, with safety and tolerability similar to placebo. Clinicaltrials.gov NCT04574362 Date registered: 2020-10-05.
Sections du résumé
BACKGROUND
BACKGROUND
Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries. Previously, a large clinical trial assessed the efficacy and safety of rimegepant ODT 75 mg for the acute treatment of migraine in adults living in China or South Korea. A post hoc subgroup analysis of this trial was performed to evaluate the efficacy and safety of rimegepant for acute treatment of migraine in adults living in China.
METHODS
METHODS
Eligible participants were ≥ 18 years of age and had a ≥ 1-year history of migraine, with 2 to 8 attacks of moderate or severe pain intensity per month and < 15 headache days per month during the 3 months before screening. Participants self-administered rimegepant ODT 75 mg or matching placebo to treat a single migraine attack of moderate or severe pain intensity. The co-primary endpoints were pain freedom and freedom from the most bothersome symptom (MBS) at 2 h post-dose. Key secondary endpoints included pain relief at 2 h post-dose, ability to function normally at 2 h post-dose, use of rescue medication within 24 h post-dose, and sustained pain freedom from 2 to 24 h and 2 to 48 h post-dose. All p values were nominal. Safety was assessed via treatment-emergent adverse events (TEAEs), electrocardiograms, vital signs, and routine laboratory tests.
RESULTS
RESULTS
Overall, 1075 participants (rimegepant, n = 538; placebo, n = 537) were included in the subgroup analysis. Rimegepant was more effective than placebo for the co-primary endpoints of pain freedom (18.2% vs. 10.6%, p = 0.0004) and freedom from the MBS (48.0% vs. 31.8%, p < 0.0001), as well as all key secondary endpoints. The incidence of TEAEs was comparable between the rimegepant (15.2%) and placebo (16.4%) groups. No signal of drug-induced liver injury was observed, and no study drug-related serious TEAEs were reported in the rimegepant group.
CONCLUSIONS
CONCLUSIONS
A single dose of rimegepant 75 mg rimegepant was effective for the acute treatment of migraine in adults living in China, with safety and tolerability similar to placebo.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov NCT04574362 Date registered: 2020-10-05.
Identifiants
pubmed: 38627638
doi: 10.1186/s10194-024-01731-4
pii: 10.1186/s10194-024-01731-4
doi:
Banques de données
ClinicalTrials.gov
['NCT04574362']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57Informations de copyright
© 2024. The Author(s) and Pfizer.
Références
Headache classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202
doi: 10.1177/0333102417738202
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 390:1211–1259. https://doi.org/10.1016/s0140-6736(17)32154-2
Yao C, Wang Y, Wang L, Liu Y, Liu J, Qi J et al (2019) Burden of headache disorders in China, 1990-2017: findings from the global burden of disease study 2017. J Headache Pain 20:102. https://doi.org/10.1186/s10194-019-1048-2
doi: 10.1186/s10194-019-1048-2
pubmed: 31699022
pmcid: 6836347
Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M (2016) Quality of life in primary headache disorders: a review. Cephalalgia 36:67–91. https://doi.org/10.1177/0333102415580099
doi: 10.1177/0333102415580099
pubmed: 25888584
Blumenfeld A, Varon S, Wilcox T, Buse D, Kawata A, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS). Cephalalgia 31:301–315. https://doi.org/10.1177/0333102410381145
doi: 10.1177/0333102410381145
pubmed: 20813784
Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S et al (2021) Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22:29. https://doi.org/10.1186/s10194-021-01243-5
doi: 10.1186/s10194-021-01243-5
pubmed: 33882816
pmcid: 8061063
Buse DC, Nahas SJ, Stewart WBF, Armand CE, Reed ML, Fanning KM et al (2023) Optimized acute treatment of migraine is associated with greater productivity in people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. J Occup Environ Med 65:e261–e268. https://doi.org/10.1097/jom.0000000000002801
doi: 10.1097/jom.0000000000002801
pubmed: 36701797
pmcid: 10090340
Zhao H, Xiao Z, Zhang L, Ford J, Zhong S, Ye W et al (2023) Real-world treatment patterns and outcomes among patients with episodic migraine in China: results from the Adelphi migraine disease specific Programme™. J Pain Res 16:357–371. https://doi.org/10.2147/jpr.S371887
doi: 10.2147/jpr.S371887
pubmed: 36762367
pmcid: 9904300
Wang X, Xing Y, Sun J, Zhou H, Yu H, Zhao Y et al (2016) Prevalence, associated factors, and impact on quality of life of migraine in a Community in Northeast China. J Oral Facial Pain Headache 30:139–149. https://doi.org/10.11607/ofph.1584
doi: 10.11607/ofph.1584
pubmed: 27128478
Raffaelli B, Rubio-Beltrán E, Cho SJ, De Icco R, Labastida-Ramirez A, Onan D et al (2023) Health equity, care access and quality in headache - part 2. J Headache Pain 24:167. https://doi.org/10.1186/s10194-023-01699-7
doi: 10.1186/s10194-023-01699-7
pubmed: 38087219
pmcid: 10717448
Martelletti P, Leonardi M, Ashina M, Burstein R, Cho SJ, Charway-Felli A et al (2023) Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain 24:140. https://doi.org/10.1186/s10194-023-01666-2
doi: 10.1186/s10194-023-01666-2
pubmed: 37884869
pmcid: 10604921
Li X, Zhou J, Tan G, Wang Y, Ran L, Chen L (2012) Diagnosis and treatment status of migraine: a clinic-based study in China. J Neurol Sci 315:89–92. https://doi.org/10.1016/j.jns.2011.11.021
doi: 10.1016/j.jns.2011.11.021
pubmed: 22153828
Liu H, Dong M, Liu K, Jia Z, Gui W, Cheng Y et al (2023) Status of diagnosis and preventative treatment for primary headache disorders: real-world data of unmet needs in China. J Headache Pain 24:119. https://doi.org/10.1186/s10194-023-01654-6
doi: 10.1186/s10194-023-01654-6
pubmed: 37653478
pmcid: 10472552
Yu S, Zhang M, Zhou J, Liu R, Wan Q, Li Y (2014) Headache care in China. Headache 54:601–609. https://doi.org/10.1111/head.12330
doi: 10.1111/head.12330
pubmed: 24666114
Liu R, Yu S, He M, Zhao G, Yang X, Qiao X et al (2013) Health-care utilization for primary headache disorders in China: a population-based door-to-door survey. J Headache Pain 14:47. https://doi.org/10.1186/1129-2377-14-47
doi: 10.1186/1129-2377-14-47
pubmed: 23731663
pmcid: 3673891
Yu S, Zhang Y, Yao Y, Cao H (2020) Migraine treatment and healthcare costs: retrospective analysis of the China health insurance research association (CHIRA) database. J Headache Pain 21:53. https://doi.org/10.1186/s10194-020-01117-2
doi: 10.1186/s10194-020-01117-2
pubmed: 32404048
pmcid: 7222520
Chinese Medical Association Group (2022) Guidelines for Diagnosis and Treatment of Migraine in China (2022 Edition). Chin J Pain Med 28:881–898
Ailani J, Burch RC, Robbins MS, on behalf of the Board of Directors of the American Headache Society (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021–1039. https://doi.org/10.1111/head.14153
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A et al (2009) EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 16:968–981. https://doi.org/10.1111/j.1468-1331.2009.02748.x
doi: 10.1111/j.1468-1331.2009.02748.x
pubmed: 19708964
Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 55:3–20. https://doi.org/10.1111/head.12499
doi: 10.1111/head.12499
pubmed: 25600718
Hutchinson S, Lipton RB, Ailani J, Reed ML, Fanning KM, Adams AM et al (2020) Characterization of acute prescription migraine medication use: results from the CaMEO study. Mayo Clin Proc 95:709–718. https://doi.org/10.1016/j.mayocp.2019.11.025
doi: 10.1016/j.mayocp.2019.11.025
pubmed: 32247344
Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML et al (2018) Migraine in America symptoms and treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 58:1408–1426. https://doi.org/10.1111/head.13407
doi: 10.1111/head.13407
pubmed: 30341895
Roessler T, Zschocke J, Roehrig A, Friedrichs M, Friedel H, Katsarava Z (2020) Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis. J Headache Pain 21:85. https://doi.org/10.1186/s10194-020-01154-x
doi: 10.1186/s10194-020-01154-x
pubmed: 32631274
pmcid: 7339552
Vo P, Paris N, Bilitou A, Valena T, Fang J, Naujoks C et al (2018) Burden of migraine in Europe using self-reported digital diary data from the migraine buddy© application. Neurol Ther 7:321–332. https://doi.org/10.1007/s40120-018-0113-0
doi: 10.1007/s40120-018-0113-0
pubmed: 30293098
pmcid: 6283800
Lyu S, Zhang CS, Sun J, Weng H, Xue CC, Guo X et al (2022) Chinese herbal medicine for migraine management: a hospital-based retrospective analysis of electronic medical records. Front Med (Lausanne) 9:936234. https://doi.org/10.3389/fmed.2022.936234
doi: 10.3389/fmed.2022.936234
pubmed: 36438031
Dodick DW, Shewale AS, Lipton RB, Baum SJ, Marcus SC, Silberstein SD et al (2020) Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health 11:2150132720963680. https://doi.org/10.1177/2150132720963680
doi: 10.1177/2150132720963680
pubmed: 33095099
pmcid: 7585888
Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115:1634–1642. https://doi.org/10.1161/circulationaha.106.181424
doi: 10.1161/circulationaha.106.181424
pubmed: 17325246
Cooper W, Doty EG, Hochstetler H, Hake A, Martin V (2020) The current state of acute treatment for migraine in adults in the United States. Postgrad Med 132:581–589. https://doi.org/10.1080/00325481.2020.1767402
doi: 10.1080/00325481.2020.1767402
pubmed: 32459561
Dong Z, Chen X, Steiner TJ, Hou L, Di H, He M et al (2015) Medication-overuse headache in China: clinical profile, and an evaluation of the ICHD-3 beta diagnostic criteria. Cephalalgia 35:644–651. https://doi.org/10.1177/0333102414552533
doi: 10.1177/0333102414552533
pubmed: 25286910
Zhang L, Novick D, Zhong S, Li J, Walker C, Harrison L et al (2023) Real-world analysis of clinical characteristics, treatment patterns, and patient-reported outcomes of insufficient responders and responders to prescribed acute migraine treatment in China. Pain Ther. https://doi.org/10.1007/s40122-023-00494-1
Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84:688–695. https://doi.org/10.1212/wnl.0000000000001256
doi: 10.1212/wnl.0000000000001256
pubmed: 25609757
pmcid: 4336107
Luo N, Qi W, Zhuang C, Di W, Lu Y, Huang Z et al (2014) A satisfaction survey of current medicines used for migraine therapy in China: is Chinese patent medicine effective compared with Western medicine for the acute treatment of migraine? Pain Med 15:320–328. https://doi.org/10.1111/pme.12277
doi: 10.1111/pme.12277
pubmed: 24524844
Edvinsson L (2019) Role of CGRP in migraine. Handb Exp Pharmacol 255:121–130. https://doi.org/10.1007/164_2018_201
doi: 10.1007/164_2018_201
pubmed: 30725283
Monthly Report: New Drug Approvals in China, September 2023 (2023). https://baipharm.chemlinked.com/news/monthly-report-new-drug-approvals-in-china-september-2023 . Accessed October 9 2023
Nurtec ODT (rimegepant) Prescribing information. https://labeling.pfizer.com/ShowLabeling.aspx?id=19036 . Accessed May 12 2023
Vydura (Rimegepant) Prescribing Information. https://www.pfizerpro.co.uk/medicine/vydura . Accessed 2023 May 12
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M et al (2019) Rimegepant, an Oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381:142–149. https://doi.org/10.1056/NEJMoa1811090
doi: 10.1056/NEJMoa1811090
pubmed: 31291516
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394:737–745. https://doi.org/10.1016/S0140-6736(19)31606-X
doi: 10.1016/S0140-6736(19)31606-X
pubmed: 31311674
Croop R, Berman G, Kudrow D, Mullin K, Thiry A, Lovegren M, et al (2024) A Multicenter, Open-Label Long-Term Safety Study of Rimegepant for the Acute Treatment of Migraine. Cephalalgia [Manuscript in Press]
Lipton RB, Conway CM, Stock EG, Stock D, Morris BA, McCormack TJ et al (2018) Efficacy, safety, and tolerability of Rimegepant 75 mg, an Oral CGRP receptor antagonist, for the acute treatment of migraine: results from a phase 3, double-blind, randomized, placebo-controlled trial, study 301. Headache: J Head Face Pain. 58:1287–1337
Yu S, Kim B-K, Guo A, Kim M-H, Zhang M, Wang Z et al (2023) Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 22:476–484. https://doi.org/10.1016/S1474-4422(23)00126-6
doi: 10.1016/S1474-4422(23)00126-6
pubmed: 37210098
Headache classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808. https://doi.org/10.1177/0333102413485658
Chinese Medical Association Group (2016) Guide to the prevention and treatment of migraine in China [Chinese]. Chin J Pain Med 22:721–727
Mayans L, Walling A (2018) Acute migraine headache: treatment strategies. Am Fam Physician 97:243–251
pubmed: 29671521
Tai FWD, McAlindon ME (2021) Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clin Med (Lond) 21:131–134. https://doi.org/10.7861/clinmed.2021-0039
doi: 10.7861/clinmed.2021-0039
pubmed: 33762373
Varga Z, Sabzwari SRA, Vargova V (2017) Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus. 9:e1144. https://doi.org/10.7759/cureus.1144
doi: 10.7759/cureus.1144
pubmed: 28491485
pmcid: 5422108
Drożdżal S, Lechowicz K, Szostak B, Rosik J, Kotfis K, Machoy-Mokrzyńska A et al (2021) Kidney damage from nonsteroidal anti-inflammatory drugs—myth or truth? Review of selected literature. Pharmacol Res Perspect 9:e00817. https://doi.org/10.1002/prp2.817
doi: 10.1002/prp2.817
pubmed: 34310861
pmcid: 8313037
Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ (2020) Small-molecule CGRP receptor antagonists: a new approach to the acute and preventive treatment of migraine. Med Drug Discov 7:100053. https://doi.org/10.1016/j.medidd.2020.100053
doi: 10.1016/j.medidd.2020.100053
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 397:51–60. https://doi.org/10.1016/s0140-6736(20)32544-7
doi: 10.1016/s0140-6736(20)32544-7
pubmed: 33338437
Mohajer A, Scripture J, L’Italien G, Harris L, Coric V, Rosen N (2022) Reduction in opioid prescription fills and morphine milligram equivalent dispensed following initiation of Nurtec ODT treatment – a real world administrative claims study (S31.010). Neurology 98:3807
doi: 10.1212/WNL.98.18_supplement.3807
Rosen N, Mohajer A, Abraham L, Brown J, Hygge Blakeman K, Jenkins A et al (2023) Reduction in barbiturate prescription fills and quantity dispensed following initiation of rimegepant treatment: a real-world administrative claims study. Headache 63:78
L’Italien G, Harris L, Mohajer A, Scripture J, Coric V, Rosen N (2022) Real world evidence of reduction in point prevalence of medication overuse headache after migraine therapy with rimegepant. Headache 62:80
Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H et al (2018) Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 19:50. https://doi.org/10.1186/s10194-018-0875-x
doi: 10.1186/s10194-018-0875-x
pubmed: 30003412
pmcid: 6043466
Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C et al (2023) Medication overuse headache. Nat Rev Dis Primers 9:5. https://doi.org/10.1038/s41572-022-00415-0
doi: 10.1038/s41572-022-00415-0
pubmed: 36732518
Saengjaroentham C, Strother LC, Dripps I, Sultan Jabir MR, Pradhan A, Goadsby PJ et al (2020) Differential medication overuse risk of novel anti-migraine therapeutics. Brain 143:2681–2688. https://doi.org/10.1093/brain/awaa211
doi: 10.1093/brain/awaa211
pubmed: 32810212
pmcid: 7523700
Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F (2020) Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia 40:892–902. https://doi.org/10.1177/0333102420938652
doi: 10.1177/0333102420938652
pubmed: 32615788
pmcid: 7412872